Health Care • Biotechnology: Pharmaceutical Preparations
$4.04 ▼ -0.19
(-4.49%)
MKT CAP: $507.1M • VOL: 2.02M
52W L $3 52W H $7
AQST // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $44.5M | $57.6M | $50.6M |
| YoY Revenue Growth % | -22.6% | +13.8% | — |
| Gross Profit | $26.0M | $39.7M | — |
| Gross Margin % | 58.3% | 69.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$71.1M | -$30.8M | -$15.1M |
| Operating Margin % | -80.0% | -53.5% | -29.9% |
| Net Income (GAAP) | -$83.8M | -$44.1M | -$7.9M |
| EBITDA (Normalized) | -$70.6M | -$30.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$52.4M | -$35.8M | -$6.4M |
| Capital Expenditures (CapEx) | $562.0K | $159.0K | — |
| Free Cash Flow (FCF) | -$53.0M | -$35.9M | -$6.4M |
| FCF Margin % | -80.0% | -62.4% | -12.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $121.2M | $71.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$33.7M | -$60.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AQST.